New Collaboration will Study Long-term Outcomes of CAR T-cell Therapy Yescarta – Lymphoma News Today
Lymphoma News Today |
New Collaboration will Study Long-term Outcomes of CAR T-cell Therapy Yescarta
Lymphoma News Today Under the terms of this agreement, CIBMTR will collect and analyze long-term safety and effectiveness data for Yescarta, the first CAR T-cell therapy approved in the U.S. for the treatment of adults with different types of lymphoma. CIBMTR collaborates … |
